Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
ID: 349964Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349964

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-279.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)" aimed at advancing research on the effects of incretin mimetics on cancer risk. This initiative seeks to promote preclinical and patient-based studies that investigate the mechanisms by which incretin mimetics, including GLP-1 and GIP-1 receptor agonists, may influence cancer risk, particularly in relation to obesity-related cancers such as thyroid and prostate cancers. The funding is intended to support diverse scientific inquiries into cancer biology, with applications encouraged from a wide range of eligible institutions, including historically black colleges, tribal colleges, and community-based organizations. Interested applicants should note that the application submission period opens on January 5, 2024, and the closing date for submissions is January 7, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-279.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-279-Full-Announcement.html
    PAR-23-279.html
    The National Cancer Institute (NCI) is inviting applications for R01 Research Project Grants aimed at understanding how incretin mimetics, specifically glucagon-like peptide (GLP-1) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP-1) receptor agonists, influence cancer risk. This funding opportunity focuses on elucidating mechanisms by which these agents could either mitigate or exacerbate cancer risks, particularly for thyroid and prostate cancers. Investigators are encouraged to submit applications that propose studies involving both animal models and human trials, provided they scrutinize specific mechanistic endpoints related to cancer development following incretin mimetic administration. Notably, the opportunity is not meant for epidemiological studies, and the proposal must include rigorous justifications if using incretin mimetics other than GLP-1 RAs. Key application dates are established, with the open date for submissions beginning January 5, 2024. This initiative reflects a commitment to exploring the therapeutic implications of incretin mimetics in oncology, amidst rising obesity-related cancer risks in the U.S., particularly given that obesity is a significant contributor to increased cancer mortality. Overall, the NCI seeks to broaden the understanding of cancer biology relating to incretin mimetics while fostering diverse scientific inquiry in the field.
    Similar Opportunities
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)" aimed at investigating how incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk. The program seeks to promote preclinical and patient-based studies that explore the mechanisms by which these agents affect cancer, especially in relation to obesity-related cancers, while attracting talented scientists to focus on long-term outcomes rather than short-term effects like weight loss and diabetes. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with applications encouraged to begin submission starting January 5, 2024, for projects with a funding period of up to five years. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and the opportunity is set to close on January 7, 2027.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 exploratory research grant titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics." This grant aims to support preclinical and patient-based studies that investigate how incretin mimetics, specifically GLP-1 and GIP-1 receptor agonists, influence cancer risk, particularly in relation to obesity-related cancers such as thyroid and prostate cancers. The funding, which amounts to a maximum of $275,000 over two years, is intended for projects that do not involve clinical trials, with applications opening in January 2024 and a submission deadline of January 7, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)." This initiative aims to promote exploratory research into the biological mechanisms by which incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk, with a focus on understanding their effects beyond diabetes treatment. The funding, which amounts to a maximum of $275,000 over two years, is intended to attract diverse researchers and institutions to fill significant gaps in current cancer biology research. Interested applicants should note that the application submission period begins on January 16, 2025, and can find further details and guidelines at the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research investigating the mechanisms by which bariatric surgery impacts cancer risk, under the title "Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)." This initiative aims to support studies that explore the long-term effects of bariatric surgery on cancer risk, moving beyond immediate outcomes such as weight loss and diabetes, and considering factors like sex, racial background, and procedure type. With a funding ceiling of $500,000 per year for up to five years, the program encourages innovative research proposals from a diverse range of eligible applicants, including educational institutions and community organizations. Applications are due by January 7, 2028, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-043.html.
    Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)." This grant aims to support innovative, investigator-initiated studies that explore how bariatric surgery influences cancer risk, moving beyond traditional short-term outcomes such as weight loss and diabetes management. Given the rising prevalence of obesity and the increasing number of bariatric surgeries performed in the U.S., this research is crucial for identifying new pathways for cancer prevention. The grant provides funding of up to $275,000 over two years, with applications due by January 16, 2025, and additional cycles available through 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-044.html.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity (PAR-23-051) aimed at investigating the mechanistic links between diet, lipid metabolism, and tumor growth and progression. This initiative seeks applications that explore how dietary patterns, particularly high-fat or ketogenic diets, influence cancer cell metabolism and tumor behavior, with a focus on the role of lipids in these processes. The program is designed to bridge the fields of nutrition and molecular metabolism, stimulate research, and develop tools to enhance understanding in this area, while emphasizing collaboration among investigators with expertise in nutrition. Applicants may request up to $500,000 annually for a maximum of five years, with the application deadline set for October 23, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)" aimed at exploring the connections between dietary factors and cancer biology. This initiative seeks applications that investigate the molecular mechanisms linking lipid metabolism to tumor growth and progression, with a particular focus on how dietary lipids influence the tumor microenvironment and associated health disparities. The program supports exploratory research with a maximum funding request of $275,000 in direct costs over two years, and applications are due by October 23, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-118.html.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)" aimed at advancing research in the intersection of nutrition and cancer biology. This initiative seeks applications that investigate the molecular mechanisms by which lipid metabolism influences tumor dynamics, particularly focusing on the effects of dietary lipids and their interactions with the tumor microenvironment. The program is designed to bridge the fields of nutrition and cancer research, with a budget cap of $500,000 per year for up to five years, encouraging innovative studies, especially those involving high-fat or ketogenic diets. Interested applicants can find more information and application guidelines at the provided NIH link, with a submission deadline of October 23, 2025, and inquiries directed to grantsinfo@nih.gov.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.